<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of metastatic mucosal melanoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of metastatic mucosal melanoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of metastatic mucosal melanoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard D Carvajal, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Omid Hamid, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charlotte Ariyan, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Russell S Berman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3461275088"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Melanomas may arise from the mucosal epithelium lining the respiratory, alimentary, and genitourinary tracts, all of which contain melanocytes, as well as from the skin.</p><p>Mucosal melanomas generally carry a worse prognosis than those arising from cutaneous sites. Our understanding of the optimal management for malignant melanoma is limited because of the rarity of this disease, its unique biology, and clinical challenges of mucosal melanoma arising from each anatomic location.</p><p>The treatment of metastatic mucosal melanoma is discussed here. The epidemiology, clinical diagnosis, and specific management of patients with locoregional mucosal melanomas arising in the head and neck, vulvovaginal, and anorectal regions, is discussed separately. The management of patients with cutaneous melanoma as well as uveal and conjunctival melanoma is also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16904.html" rel="external">"Locoregional mucosal melanoma: Epidemiology, clinical diagnosis, and treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/85841.html" rel="external">"Overview of the management of advanced cutaneous melanoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7615.html" rel="external">"Adjuvant and neoadjuvant therapy for cutaneous melanoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7617.html" rel="external">"Initial management of uveal and conjunctival melanomas"</a>.)</p><p></p><p class="headingAnchor" id="H389391203"><span class="h1">INITIAL THERAPY</span></p><p>Data are limited for the optimal management of patients with <strong>metastatic</strong> melanoma arising from a mucosal site. Although systemic treatments have been extrapolated from metastatic cutaneous melanoma, these approaches are evolving as more clinical trials specifically evaluate patients with mucosal melanoma. (See <a class="local">'Investigational approaches'</a> below.)</p><p class="headingAnchor" id="H2131903443"><span class="h2">Treatment approach</span><span class="headingEndMark"> — </span>For patients with treatment-naïve mucosal melanoma, we offer enrollment in clinical trials, if available. For those who are ineligible for or are unable to access clinical trials, we suggest initial treatment with checkpoint inhibitor immunotherapy that incorporates a programmed cell death 1 (PD-1) inhibitor rather than other systemic agents. Options for immunotherapy include the combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef130970" href="/d/graphic/130970.html" rel="external">table 1</a>) or single-agent immunotherapy such as nivolumab  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 2</a>) or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 3</a>). The choice of therapy is individualized based on patient performance status, ability to tolerate combination immunotherapy, and the goals of therapy. (See <a class="local">'Nivolumab plus ipilimumab'</a> below and <a class="local">'Single-agent immunotherapy'</a> below.)</p><p>Surgery and/or radiation therapy (RT) may also be used to palliate symptomatic lesions. (See  <a class="medical medical_review" href="/d/html/131562.html" rel="external">"Metastatic melanoma: Surgical management"</a> and  <a class="medical medical_review" href="/d/html/7614.html" rel="external">"Radiation therapy in the management of melanoma"</a>.)</p><p class="headingAnchor" id="H4092637162"><span class="h2">Nivolumab plus ipilimumab</span><span class="headingEndMark"> — </span>For patients with metastatic mucosal melanoma and good performance status who are anticipated to tolerate the potential toxicities of combination immunotherapy, we suggest initial therapy with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef130970" href="/d/graphic/130970.html" rel="external">table 1</a>) over single-agent immunotherapy, as this regimen offers the opportunity to achieve complete responses and treatment-free survival, extrapolating from the approach used for metastatic cutaneous melanoma. Of note, the clinical efficacy of nivolumab plus ipilimumab in metastatic mucosal melanoma is lower than that seen for metastatic cutaneous melanoma. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Treatment-free survival'</a>.)</p><p>However, single-agent immunotherapy is a reasonable alternative to <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in patients with metastatic mucosal melanoma. Although a subset analysis of patients with mucosal melanoma in a randomized phase III trial suggested better response rates for nivolumab plus ipilimumab, it failed to demonstrate a statistically significant overall survival (OS) or progression-free survival (PFS) benefit over single-agent immunotherapy in this population. In addition, subsequent observational data comparing single-agent immunotherapy with nivolumab plus ipilimumab in real world patient populations with mucosal melanoma also suggest similar efficacy but less toxicity with this approach. (See <a class="local">'Single-agent immunotherapy'</a> below.)</p><p>A randomized phase III trial (CheckMate-067), which confirmed the efficacy of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in metastatic melanoma, included a subgroup of 79 patients with mucosal melanoma treated with either nivolumab and ipilimumab in combination or as single agents [<a href="#rid1">1</a>]. In preliminary results of this post-hoc subset analysis, at minimum follow-up of 60 months, compared with either nivolumab or ipilimumab as single agents, nivolumab plus ipilimumab was associated with the highest five-year objective response rate (43 versus 30 versus 7 percent, respectively). Complete response rates were also higher with nivolumab plus ipilimumab (14 percent) relative to nivolumab (4 percent) or ipilimumab (0 percent) monotherapy. Although nivolumab plus ipilimumab demonstrated higher five-year PFS (29 versus 14 percent, hazard ratio [HR] 0.69, 95% CI 0.36-1.33) and five-year OS (36 versus 17, HR 0.73, 95% CI 0.38-1.39) than single-agent nivolumab, these results were not statistically significant [<a href="#rid1">1</a>]. Grade ≥3 treatment-related adverse event rates were 54, 26, and 25 percent, respectively, which were similar to the overall population.</p><p>The efficacy outcomes for <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in patients with mucosal melanoma are generally less favorable than that seen in the overall population of patients with cutaneous melanoma [<a href="#rid2">2,3</a>]. (see  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Nivolumab plus ipilimumab (preferred)'</a>). </p><p class="bulletIndent1"><span class="glyph">●</span>A combined analysis of six studies identified a subset of 35 patients with advanced mucosal melanoma treated with the combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid2">2</a>]. Compared with 326 patients with cutaneous melanoma treated with nivolumab plus ipilimumab, those with mucosal melanoma who received nivolumab plus ipilimumab demonstrated lower objective response rates (37 versus 60 percent) and PFS (median 5.9 versus 11.7 months). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single-arm phase IIIb trial (CheckMate 401) of 533 patients with unresectable stage III-IV melanoma treated with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, the two-year OS was lower for patients with mucosal melanoma relative to the entire study population (38 versus 63 percent) [<a href="#rid3">3</a>]. </p><p></p><p class="headingAnchor" id="H4271557470"><span class="h2">Single-agent immunotherapy</span><span class="headingEndMark"> — </span>For patients with treatment-naïve metastatic mucosal melanoma, single-agent PD-1 inhibitors (<a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 2</a>), <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 3</a>)) are a reasonable alternative to combination immunotherapy, as observational data in real-world patient populations with mucosal melanoma suggest similar efficacy with less toxicity with this approach [<a href="#rid4">4</a>]. Single-agent immunotherapy is also an option for patients who decline or are anticipated to not tolerate the potential toxicities of combination immunotherapy.</p><p><a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a> and <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> prolong survival in patients with advanced cutaneous melanoma. Although there are no randomized clinical trials specifically addressing the activity of these agents in patients with mucosal melanoma, efficacy has been observed in this subset in post-hoc analyses of trials enrolling a more general population [<a href="#rid2">2,5-7</a>]. Compiled data from clinical trials focused on all subsets of patients with metastatic melanoma suggest that those with mucosal melanoma respond less well to single-agent immunotherapy than patients with cutaneous melanoma.</p><p>In an exploratory post-hoc analysis of three randomized trials (KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006) enrolling almost 1600 patients with stage III or IV melanoma, 84 patients had mucosal melanoma, of whom 33 had received prior <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid6">6</a>]. Among patients with mucosal melanoma, treatment with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> (at several doses) resulted in an overall objective response rate of 19 percent, and median PFS and OS of 2.8 and 11.3 months, respectively. Median duration of response was 27.6 months, suggesting durable antitumor activity.</p><p>Subsequent observational studies in real-world populations suggest similar efficacy but lower toxicity for single-agent immunotherapy (PD-1 inhibitors) compared with combination immunotherapy (PD-1 plus CTLA-4 inhibitors) [<a href="#rid4">4,8</a>]. As an example, a retrospective cohort study of 329 patients from Japan with advanced mucosal melanoma demonstrated no significant differences in objective response rates (26 versus 29 percent), PFS (median 6 versus 7 months), or OS (median 20 months each), but lower grade ≥3 toxicity rates (17 versus 53 percent) for single-agent immunotherapy versus combination immunotherapy [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H3048557508"><span class="h1">SUBSEQUENT THERAPY</span><span class="headingEndMark"> — </span>For subsequent-line therapy, the choice of therapy is determined by the presence or absence of an actionable molecular alterations such as <em>BRAF</em> V600 or <em>KIT</em>. Clinical trials are encouraged, where available.</p><p class="headingAnchor" id="H4290139874"><span class="h2">Approach to mutational testing</span><span class="headingEndMark"> — </span>All patients with mucosal melanoma should have their tumors assayed for the presence of a driver mutation at the V600 site in <em>BRAF</em>. Patients with a tumor that does not contain a <em>BRAF</em> mutation should be assessed using next-generation sequencing for the presence of an actionable driver mutation, such as <em>KIT</em> or less common driver alterations such as <em>NTRK</em> fusions [<a href="#rid9">9</a>]. Further details are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Approach to genetic assay'</a>.)</p><p class="headingAnchor" id="H154498337"><span class="h2">Patients with actionable mutations</span></p><p class="headingAnchor" id="H2779821008"><span class="h3">KIT mutation</span><span class="headingEndMark"> — </span>For those patients without a V600 <em>BRAF</em> mutation and with a <em>KIT</em> (exon 11 or 13) mutation, we offer <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>, a KIT inhibitor, as subsequent-line therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imatinib</strong><strong> </strong>– Approximately 25 percent of patients with mucosal melanoma have somatic mutations or amplification of <em>KIT</em> [<a href="#rid10">10,11</a>]. In these patients, <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>, a small molecule inhibitor of KIT and other tyrosine kinases, is an important treatment option, particularly those with symptomatic disease and those who have progressed on or are ineligible for immunotherapy. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'KIT mutations (acral and mucosal melanoma)'</a> and  <a class="medical medical_review" href="/d/html/16540.html" rel="external">"The molecular biology of melanoma", section on 'Acral and mucosal melanoma'</a>.)</p><p></p><p class="bulletIndent1">In initial clinical trials, <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> was ineffective in a molecularly unselected patient population with advanced melanoma [<a href="#rid12">12-14</a>], but observational studies demonstrated rapid and durable tumor responses in patients with melanoma harborin<em>g KIT</em> mutations [<a href="#rid15">15,16</a>]. In subsequent phase II trials of patients with<em> KIT</em> alterations in exon 11 (L576P) or exon 13 (K642E), overall response rates ranged from approximately 16 to 29 percent, including some with durable responses [<a href="#rid10">10,17,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other KIT inhibitors </strong>– <a class="drug drug_general" data-topicid="9448" href="/d/drug information/9448.html" rel="external">Nilotinib</a> also has clinical efficacy in patients with <em>KIT</em>-mutant melanoma [<a href="#rid19">19-21</a>]. As an example, in one phase II study, the partial response rate for nilotinib was 26 percent [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">Patients with<em> KIT</em>-mutant melanoma involving exon 11 or 13 have also been reported to respond to other KIT inhibitors, such as <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> [<a href="#rid22">22</a>], <a class="drug drug_general" data-topicid="8852" href="/d/drug information/8852.html" rel="external">dasatinib</a> [<a href="#rid23">23</a>], and <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid24">24</a>].</p><p></p><p class="headingAnchor" id="H592450483"><span class="h3">TRK fusions</span><span class="headingEndMark"> — </span>Patients with mucosal melanoma and <em>TRK</em> fusion-positive disease respond to therapies such as <a class="drug drug_general" data-topicid="119755" href="/d/drug information/119755.html" rel="external">larotrectinib</a> and <a class="drug drug_general" data-topicid="122336" href="/d/drug information/122336.html" rel="external">entrectinib</a>. The efficacy of these agents in metastatic melanoma is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'TRK fusions'</a> and  <a class="medical medical_review" href="/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy"</a>.)</p><p class="headingAnchor" id="H2688472108"><span class="h3">BRAF mutation</span><span class="headingEndMark"> — </span>We offer the combination of BRAF plus MEK inhibitors to patients with metastatic mucosal melanoma harboring a <em>BRAF</em> V600 mutation who have progressed on or are ineligible for checkpoint inhibitor immunotherapy, using a similar approach to those with metastatic cutaneous melanoma. Such patients are uncommon, as approximately 10 percent or less of mucosal melanomas harbor activating mutations in <em>BRAF</em>. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Choice of BRAF plus MEK inhibitor therapy'</a> and  <a class="medical medical_review" href="/d/html/16540.html" rel="external">"The molecular biology of melanoma", section on 'Acral and mucosal melanoma'</a>.)</p><p class="headingAnchor" id="H119349293"><span class="h3">Other mutations</span><span class="headingEndMark"> — </span>Molecular studies have noted other potential therapeutic targets in mucosal melanoma, including <em>SF3B1</em> mutation, <em>CDK4</em> amplifications, and <em>CDKN2A</em> gene deletions, which are under investigation [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H3701804219"><span class="h2">Patients without actionable mutations</span></p><p class="headingAnchor" id="H1932626805"><span class="h3">Antiangiogenic approaches</span><span class="headingEndMark"> — </span>For patients with progressive disease whose tumors lack actionable mutations, we reserve the use of regimens that incorporate antiangiogenic agents. In these patients, we suggest the addition of <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> to <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, which improved overall survival (OS) and progression-free survival (PFS) in a phase II trial [<a href="#rid26">26</a>]. Other antiangiogenic therapies remain investigational, and clinical trials are encouraged, where available.</p><p>Mucosal melanoma is a highly vascularized tumor suggesting that antiangiogenic therapeutic approaches may provide antitumor efficacy. Data are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carboplatin</strong><strong> plus </strong><strong>paclitaxel</strong><strong> and </strong><strong>bevacizumab</strong><strong> </strong>– In a randomized phase II trial of 114 patients with advanced treatment-naive mucosal melanoma, the addition of <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> to the combination of <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, improved PFS (median 4.8 versus 3 months, hazard ratio [HR] 0.461, 95% CI 0.306-0.695) and OS (median 13.6 versus 9 months; HR 0.611; 95% CI 0.407-0.917) [<a href="#rid26">26</a>]. Objective response rates were 19.7 and 13.2 percent, respectively. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="143227" href="/d/drug information/143227.html" rel="external">Toripalimab</a><strong> plus </strong><strong>axitinib</strong> – In a phase Ib trial, the combination of toripalimab (a programmed cell death 1 [PD-1] inhibitor) with <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a> (a vascular endothelial growth factor receptor inhibitor) demonstrated an objective response rate of 48 percent in patients with metastatic disease [<a href="#rid27">27</a>]. Median PFS was eight months and three-year OS was 31 percent. Although toripalimab has regulatory approval in China for patients with metastatic melanoma, the combination of toripalimab and axitinib in patients with metastatic mucosal melanoma remains investigational.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other antiangiogenic agents </strong>– The efficacy of other therapies in metastatic melanoma, such as <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Pembrolizumab plus lenvatinib'</a>.)</p><p></p><p class="headingAnchor" id="H1121954240"><span class="h3">Agents with limited roles</span><span class="headingEndMark"> — </span>In patients with metastatic mucosal melanoma, there is a limited role for chemotherapy either alone or in combination with <a class="drug drug_general" data-topicid="8563" href="/d/drug information/8563.html" rel="external">interferon alfa-2b</a> and/or interleukin (IL-2). Studies show minimal efficacy for this approach, similar to those with cutaneous melanoma. Access to interferon alfa-2b is also limited as the manufacturer has discontinued production. (See  <a class="medical medical_review" href="/d/html/15406.html" rel="external">"Cytotoxic chemotherapy for metastatic melanoma"</a> and  <a class="medical medical_review" href="/d/html/15407.html" rel="external">"Interleukin 2 and experimental immunotherapy approaches for advanced melanoma"</a>.)</p><p>Historical outcomes with cytotoxic chemotherapy alone have been poor. In one retrospective study, 74 patients were evaluated for response to first-line and 43 were evaluated for response to second-line systemic therapy [<a href="#rid28">28</a>]. Cytotoxic therapy represented 82 and 51 percent of first-line and second-line regimens, respectively. The best response achieved in the setting of initial therapy was similar for single-agent (10 percent) and combination alkylator therapy (8 percent). Median OS from first-line treatment was 10.3 months.</p><p>Data also suggest limited clinical responses for cisplatin-based chemotherapy plus <a class="drug drug_general" data-topicid="8563" href="/d/drug information/8563.html" rel="external">interferon alfa-2b</a> and/or IL-2 in patients with mucosal melanoma of the anorectal [<a href="#rid29">29</a>], vulvovaginal [<a href="#rid30">30</a>], and head and neck regions [<a href="#rid31">31</a>]. Additionally, the addition of these biologic agents to chemotherapy failed to show a survival benefit and had significant toxicity in a phase III trial (E3695) of advanced cutaneous melanoma [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/15407.html" rel="external">"Interleukin 2 and experimental immunotherapy approaches for advanced melanoma", section on 'Alternative interleukin 2 regimens'</a>.)</p><p class="headingAnchor" id="H1642153174"><span class="h1">INVESTIGATIONAL APPROACHES</span><span class="headingEndMark"> — </span>Mucosal melanoma is rare and carries a poor prognosis, and data are limited for the optimal treatment approach. Clinical trials are encouraged, where available.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nemvaleukin alfa</strong> – Nemvaleukin alfa, an engineered IL-2 variant immunotherapy [<a href="#rid33">33</a>], remains under investigation for patients with mucosal melanoma previously treated with single-agent PD-1 inhibitors in the ARTISTRY-6 trial (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04830124&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPOJWEtnVtIGVVnTcsxqsOgDo%2Bxd9q6cZhJXGQUYM%2FBQaQ%3D%3D&amp;TOPIC_ID=138441" target="_blank">NCT04830124</a>).</p><p></p><p class="headingAnchor" id="H2540616270"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118501.html" rel="external">"Society guideline links: Melanoma screening, prevention, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H3232483200"><span class="h1">INFORMATION FOR PATIENTS</span></p><p>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15499.html" rel="external">"Patient education: Melanoma skin cancer (The Basics)"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/892.html" rel="external">"Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/889.html" rel="external">"Patient education: Melanoma treatment; localized melanoma (Beyond the Basics)"</a>) </p><p></p><p class="headingAnchor" id="H4107055639"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enrollment in clinical trials</strong> –<strong> </strong>For patients with treatment-naïve metastatic mucosal melanoma, we offer enrollment in clinical trials, if available. Mucosal melanoma is rare and carries a poor prognosis, and data are limited for the optimal treatment approach. (See <a class="local">'Investigational approaches'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong> – For those who are ineligible for clinical trials, we suggest initial treatment with checkpoint inhibitor immunotherapy that incorporates a single-agent programmed cell death 1 (PD-1) inhibitor rather than other systemic agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Eligible for combination immunotherapy </strong>– For patients with metastatic mucosal melanoma and good performance status who are anticipated to tolerate the potential toxicities of combination immunotherapy, we suggest initial therapy with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef130970" href="/d/graphic/130970.html" rel="external">table 1</a>) over single-agent immunotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Nivolumab plus ipilimumab offers the opportunity to achieve complete responses and treatment-free survival, extrapolating from the approach used for metastatic cutaneous melanoma. Of note, this regimen has less clinical efficacy in metastatic mucosal melanoma compared with metastatic cutaneous melanoma. (See <a class="local">'Nivolumab plus ipilimumab'</a> above.)</p><p></p><p class="bulletIndent2">However, single-agent PD-1 inhibitors (<a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 2</a>), <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 3</a>)) are a reasonable alternative to combination immunotherapy, as clinical trials and observational data in real-world patient populations with mucosal melanoma suggest similar efficacy but less toxicity with this approach. (See <a class="local">'Single-agent immunotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ineligible for combination immunotherapy</strong> – Single-agent immunotherapy is also an option for patients who decline or are anticipated to not tolerate the potential toxicity of combination immunotherapy with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>. (See <a class="local">'Single-agent immunotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent therapy </strong>– For patients with metastatic disease who progress on or are ineligible for checkpoint inhibitor immunotherapy, the choice of therapy is determined by the presence of absence of an actionable molecular alteration. (See <a class="local">'Subsequent therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with actionable mutations </strong>– For patients without a<em> BRAF</em> mutation, next-generation sequencing can be used to evaluate for actionable mutations and participation into clinical trials. (See <a class="local">'Patients without actionable mutations'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>KIT</em></strong><strong> mutation</strong> – For those with a <em>KIT</em> mutation, we suggest <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> rather than other systemic agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'KIT mutation'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>TRK</em></strong><strong> fusion-positive</strong> – For those with <em>TRK</em> fusion-positive disease, we offer either <a class="drug drug_general" data-topicid="119755" href="/d/drug information/119755.html" rel="external">larotrectinib</a> or <a class="drug drug_general" data-topicid="122336" href="/d/drug information/122336.html" rel="external">entrectinib</a>. (See <a class="local">'TRK fusions'</a> above.)</p><p></p><p class="bulletIndent2">For the uncommon patient with a <em>BRAF</em> V600 mutation, we offer the combination of BRAF plus MEK inhibitors, using a similar approach to those with cutaneous melanoma. (See <a class="local">'BRAF mutation'</a> above and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Choice of BRAF plus MEK inhibitor therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients without actionable mutations</strong> – For patients without actionable mutations who progress on immunotherapy, we suggest the addition of <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> to <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Patients without actionable mutations'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Shoushtari AN, Wagstaff J, Ascierto PA, et al. CheckMate 067: Long-term outcomes in patients with mucosal melanoma. J Clin Oncol 2020; 36:15S.</a></li><li><a class="nounderline abstract_t">D'Angelo SP, Larkin J, Sosman JA, et al. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. J Clin Oncol 2017; 35:226.</a></li><li><a class="nounderline abstract_t">Dummer R, Corrie P, Gutzmer R, et al. First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. J Clin Oncol 2023; 41:3917.</a></li><li><a class="nounderline abstract_t">Nakamura Y, Namikawa K, Yoshikawa S, et al. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study). ESMO Open 2021; 6:100325.</a></li><li><a class="nounderline abstract_t">Shoushtari AN, Munhoz RR, Kuk D, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer 2016; 122:3354.</a></li><li><a class="nounderline abstract_t">Hamid O, Robert C, Ribas A, et al. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer 2018; 119:670.</a></li><li><a class="nounderline abstract_t">Nathan P, Ascierto PA, Haanen J, et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer 2019; 119:168.</a></li><li><a class="nounderline abstract_t">Dimitriou F, Namikawa K, Reijers ILM, et al. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Ann Oncol 2022; 33:968.</a></li><li><a class="nounderline abstract_t">Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2022; 40:1231.</a></li><li><a class="nounderline abstract_t">Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305:2327.</a></li><li><a class="nounderline abstract_t">Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24:4340.</a></li><li><a class="nounderline abstract_t">Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005; 92:1398.</a></li><li><a class="nounderline abstract_t">Wyman K, Atkins MB, Prieto V, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006; 106:2005.</a></li><li><a class="nounderline abstract_t">Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008; 99:734.</a></li><li><a class="nounderline abstract_t">Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008; 26:2046.</a></li><li><a class="nounderline abstract_t">Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008; 21:492.</a></li><li><a class="nounderline abstract_t">Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29:2904.</a></li><li><a class="nounderline abstract_t">Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013; 31:3182.</a></li><li><a class="nounderline abstract_t">Carvajal RD, Lawrence DP, Weber JS, et al. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res 2015; 21:2289.</a></li><li><a class="nounderline abstract_t">Lee SJ, Kim TM, Kim YJ, et al. Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). Oncologist 2015; 20:1312.</a></li><li><a class="nounderline abstract_t">Guo J, Carvajal RD, Dummer R, et al. Efficacy and Safety of Nilotinib in Patients With KIT-Mutated Metastatic or Inoperable Melanoma: Final Results From the Global, Single-Arm, Phase II TEAM Trial. Ann Oncol 2017.</a></li><li><a class="nounderline abstract_t">Quintás-Cardama A, Lazar AJ, Woodman SE, et al. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008; 5:737.</a></li><li><a class="nounderline abstract_t">Kalinsky K, Lee S, Rubin KM, et al. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer 2017; 123:2688.</a></li><li><a class="nounderline abstract_t">Zhu Y, Si L, Kong Y, et al. Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma. J Clin Oncol 2009; 27S: ASCO #e20017.</a></li><li><a class="nounderline abstract_t">Indini A, Roila F, Grossi F, et al. Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review. Int J Mol Sci 2021; 23.</a></li><li><a class="nounderline abstract_t">Yan X, Sheng X, Chi Z, et al. Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. J Clin Oncol 2021; 39:881.</a></li><li><a class="nounderline abstract_t">Li S, Wu X, Yan X, et al. Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. J Immunother Cancer 2022; 10.</a></li><li><a class="nounderline abstract_t">Shoushtari AN, Bluth MJ, Goldman DA, et al. Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. Melanoma Res 2017; 27:57.</a></li><li><a class="nounderline abstract_t">Kim KB, Sanguino AM, Hodges C, et al. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer 2004; 100:1478.</a></li><li><a class="nounderline abstract_t">Harting MS, Kim KB. Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma. Melanoma Res 2004; 14:517.</a></li><li><a class="nounderline abstract_t">Bartell HL, Bedikian AY, Papadopoulos NE, et al. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 2008; 30:1592.</a></li><li><a class="nounderline abstract_t">Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26:5748.</a></li><li><a class="nounderline abstract_t">Lopes JE, Sun L, Flick HL, et al. Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys. J Pharmacol Exp Ther 2021; 379:203.</a></li></ol></div><div id="topicVersionRevision">Topic 138441 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : CheckMate 067: Long-term outcomes in patients with mucosal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28056206" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37307514" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34839104" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27533633" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The efficacy of anti-PD-1 agents in acral and mucosal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30202085" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31445199" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35716907" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175857" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21642685" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : KIT as a therapeutic target in metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908931" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Somatic activation of KIT in distinct subtypes of melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846297" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Lack of clinical efficacy of imatinib in metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16565971" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18728664" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Phase II trial of imatinib mesylate in patients with metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18421059" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Major response to imatinib mesylate in KIT-mutated melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18510589" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690468" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23775962" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25695690" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26424760" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28327988" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy and Safety of Nilotinib in Patients With KIT-Mutated Metastatic or Inoperable Melanoma: Final Results From the Global, Single-Arm, Phase II TEAM Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18936790" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28334439" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35008570" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33444116" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35193932" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27792058" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15042682" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Biochemotherapy in patients with metastatic anorectal mucosal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15577323" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18798304" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Biochemotherapy in patients with advanced head and neck mucosal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19001327" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34362793" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
